Lisa M. Eubanks, Ph.D., et al. stated in an Aug. 9, 2006 Molecular Pharmaceutics journal article titled “A Molecular Link Between the Active Component of Marijuana and Alzheimer’s Disease Pathology” (PDF 143KB):
“In contrast to previous studies aimed at utilizing cannabinoids in Alzheimer’s disease therapy, our results provide a mechanism whereby the THC molecule can directly impact Alzheimer’s disease pathology.[…]
It is noteworthy that THC is a considerably more effective inhibitor […] than the approved drugs for Alzheimer’s disease treatment, donepezil and tacrine, which reduced [protein deposits in the brain] by only 22% and 7%, respectively, at twice the concentration used in our studies. […]
THC and its analogues may provide an improved therapeutic for Alzheimer’s disease [by] simultaneously treating both the symptoms and progression of Alzheimer’s disease.” b
Aug. 9, 2006 Lisa M. Eubanks
Maria L. de Ceballos, Ph.D., et al. wrote in their Feb. 23, 2005 article “Prevention of Alzheimer’s disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockage of Microglial Activation,” published in the Journal of Neuroscience (Vol. 25 No. 8, pp.1904-1913):
“Our results indicate that cannabinoid receptors are important in the pathology of AD [Alzheimer’s disease] and that cannabinoids succeed in preventing the neurodegenerative process occurring in the disease.”
Feb. 23, 2005 Maria L. de Ceballos
The Oregon Department of Health Services stated in a June 14, 2000 press release:
“After reviewing the recommendations of an expert panel, we have decided to add Agitation of Alzheimer’s disease to the list of medical conditions for which a doctor may write a statement of support for the medical use of marijuana.”
June 14, 2000 Oregon Department of Health Services
Source: ProCon.org
Copyright: 2010 ProCon.org
